



CANCER BIOMARKERS CONFERENCE VI • #CBCVI

Saturday, September 16, 2023
7 a.m. – 5 p.m.

Sunday, September 17, 2023
7 a.m. – 12:30 p.m.

Pre-Conference Bootcamp (Non-CME) Friday, September 15, 2023 – 8:30 a.m. – 5 p.m.

David Rubenstein Forum • Chicago, IL

Friday, September 15, 2023
Bootcamp

Program Director – Daniel Arber, MD
Chair of Pathology, University of Chicago Medicine
Donald West and Mary Elizabeth King Professor of Pathology at the University of Chicago

- 8:30-9:45** **Check In, Breakfast, and Visit Sustaining Partners & Exhibitors**
- 10:00-11:30** **Welcome**
Daniel Arber, MD /Timothy Allen, MD, JD
Bob McGonnagle, BA
- Panel 1**
Town and Gown Update 2023: Biomarkers and Targeted Therapies Across the Spectrum of Clinical Practice
Invited Panelists:
- 11:30-12:00** **Break and Visit Sustaining Partners & Exhibitors**
- 12:00-1:00** **Panel 2**
Reference Labs in Focus on Biomarker Testing
Invited Panelists:
- 1:00-2:00** **Lunch with Table Topic Discussion and Visit Sustaining Partners & Exhibitors**

- 2:00-3:00** **Panel 3**
Winning Technologies Emerging?
Invited Panelists:
- 3:00-4:00** **Panel 4**
A Focus on Society Patients
Invited Panelists:
- 4:00-5:00** **Summation, Q&A, Reflections on the Day**
Timothy Allen, MD, JD / Daniel Arber, MD

All panels are designed to be fully interactive with attendees. Panel members, who may be subject to change, will offer only brief remarks, followed by questions and discussion. All tumor types, practice settings, biomarkers and technologies will be addressed in any and all panel sessions as they arise.



CANCER BIOMARKERS CONFERENCE VI • #CBCVI

Saturday, September 16, 2023
7 a.m. – 5 p.m.

Sunday, September 17, 2023
7 a.m. – 12:30 p.m.

Pre-Conference Bootcamp (Non-CME) Friday, September 15, 2023 – 8:30 a.m. – 5 p.m.

David Rubenstein Forum • Chicago, IL

Saturday, September 16, 2023

Program Director – Daniel Arber, MD

Chair of Pathology, University of Chicago Medicine

Donald West and Mary Elizabeth King Professor of Pathology at the University of Chicago

- 7:00-8:00** **Check In, Breakfast and Visit Sustaining Partners & Exhibitors**
- 8:00-8:30** **Keynote Address: Biomarkers in Myeloid Neoplasms**
Daniel Arber, MD
Donald West and Mary Elizabeth King Professor, Chairman, Department of Pathology,
University of Chicago
- 8:30-9:00** **Biomarker Testing in Small Specimens (biopsy vs. FNA)**
Sinchita Roy Chowduri, MD
- 9:00-9:30** **Predictive Biomarkers in Malignant Gynecologic Neoplasms**
Ricardo Lastra, MD
- 9:30-10:00** **Molecular Biomarker Testing in Genitourinary Neoplasms**
Donna Hansel, MD
- 10:00-10:30** **Break and Visit Sustaining Partners & Exhibitors**
- 10:30-11:00** **The Second Revision of the Lung Cancer Molecular Testing Guidelines**
Neal Linderman, MD
- 11:00-11:30** **Molecular and Genomic Biomarkers of Gastrointestinal Cancers for Precision Therapies**

Antonia Sepulveda, MD

- 11:30-12:00 Predictive Biomarkers for Immunotherapy in Lung Cancer**
Mari Mina-Kenudson, MD
Director, Pulmonary Pathology, Massachusetts General Hospital, Professor of Pathology,
Harvard Medical School
- 12:00- 12:30 Panel Discussion**
- 12:30-1:30 Lunch and Visit Sustaining Partners & Exhibitors**
- 1:30 -2:00 Biomarkers in Colorectal Carcinoma: What's New in 2023?**
Rhonda Yantiss, MD
- 2:00 – 2:30 Update on Dermatopathologic Molecular Biomarker Testing**
Sara Shalin, MD
- 2:30-3:00 Biomarkers in Breast Cancer**
Deborah Dillon, MD, PhD
Director, Breast Biorepository and Clinical Trials Lab
Dana-Farber Cancer Institute, Harvard Medical School
- 3:00-3:30 Break and Visit Sustaining Partners & Exhibitors**
- 3:30-4:00 Genetic Molecular Biomarker Testing**
Jonathan Nowak, MD
- 4:00-4:30 Panel Discussion/Day 1 Wrap Up**
- 4:30 Adjourn**



CANCER BIOMARKERS CONFERENCE VI • #CBCVI

Saturday, September 16, 2023

7 a.m. – 5 p.m.

Sunday, September 17, 2023

7 a.m. – 12:30 p.m.

Pre-Conference Bootcamp (Non-CME) Friday, September 15, 2023 – 8:30 a.m. – 5 p.m.

David Rubenstein Forum • Chicago, IL

Sunday, September 17, 2023

Program Director – Timothy Allen, MD, JD

Chair of Pathology, Oakland University William Beaumont School of Medicine

Chief of Pathology Service line – Beaumont Health, Physician Executive,

Pathology – Beaumont Medical Group, Chief of Pathology – Beaumont Royal Oak Hospital

- 7:00-8:00** **Check In, Breakfast and Visit Sustaining Partners & Exhibitors**
- 8:00-8:30** **A Contemporary Biomarker-Driven Approach to Diffuse Glioma Diagnosis**
Daniel Brat, MD
Magerstadt Professor and Chair, Department of Pathology, Northwestern University
Feinberg School of Medicine
- 8:30-9:00** **Update on Molecular Biomarker Testing in Neuropathology**
Jose Otero, MD
- 9:00-9:30** **Reflex Biomarker Testing for Early Stage Lung Cancer: Babinski or Boon?**
Eric Bernicker, MD
- 9:30-10:00** **Drug Resistance to Personalized Therapy in Gastrointestinal Cancers**
Namrata Setia, MD
- 10:00-10:30** **Biomarkers in T-Cell Lymphoma**
Andy Feldman, MD
- 10:30-11:00** **Panel Discussion**
Moderator: Timothy Allen, MD, JD
Chair of Pathology, Oakland University William Beaumont School of Medicine
Chief of Pathology Service line – Beaumont Health, Physician Executive,

Pathology – Beaumont Medical Group, Chief of Pathology – Beaumont Royal Oak Hospital

11:00-11:30 Break and Visit Sustaining Partners & Exhibitors

11:30-12:00 Update on Lung Cancer Biomarker Testing

Alain Borczuk, MD

Vice Chairman and Director of Anatomic Pathology, Chief of Thoracic Pathology, Weill Cornell Medicine

11:30-12:00 Molecular Aspects of Mesothelioma

Lucian Chirieac, MD

Associate Professor of Pathology, Harvard Medical School
Brigham and Women's Hospital

12:00- 12:30 Biomarkers in B-cell Lymphoma

Genevieve (Eve) Crane, MD, PhD

Assistant Professor of Pathology, Division of Immunopathology, Weill Cornell Medicine, Weill Cornell Medical College

Predict emerging technologies that may improve patient care by identifying early evidence of treatment failure or disease evolution.

12:30 Adjourn - 30 minutes have been allotted for the completion of the course evaluation. Please complete the evaluation/claim your credit by Wednesday, September 14, 2023. The evaluation time is incorporated into the last session of the day.

Disclosure

No planners or speakers have any relevant conflicts of interest to disclose with the exception of **Dr. Daniel Arber**, who is a consultant for Jazz Pharma. Any potential conflicts of interest have been mitigated through an attestation that he will not present recommendations regarding the use of drugs or devices from companies with which he has a financial relationship. **Dr. Mari Mino-Kenudson** is a consultant for AstraZeneca, BMS, Sanofi, and Janssen Oncology. She also receive royalties from Elsevier. Any potential conflicts of interest have been mitigated through an attestation that she will not present recommendations regarding the use of drugs or devices from companies with which she have a financial relationship. **Dr. Deborah Dillon** is a consultant/member of the Academic Advisory Board for Oncology Analytics and have received a research grant from Canon, Inc. Any potential conflicts of interest have been mitigated through an attestation that she will not present recommendations regarding the use of drugs or devices from companies with which she have a financial relationship. **Dr. Jonathan Nowak** received funding for pilot technology feasibility studies from NanoString, Illumina, and Akoya Biosciences and a research grant from Akoya Biosciences. Any potential conflicts of interest have been mitigated through an attestation that he will not present recommendations regarding the use of drugs or devices from companies with which he have a financial relationship.

Continuing Educational Credit

Physician Credit

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.